Jump to content
TB-500 Source

A precision research ledger on TB-500 (Ac-LKKTETQ) — the actin-binding thymosin beta-4 fragment tracked study by study, with the human-data gaps and compounded-access status reconciled in plain figures.

HOW WE CHECK THE CLAIMS

About TB-500 Source

We read the cited study, name who or what was tested, and report the result. No product or service is offered here.

What TB-500 Source does for you

TB-500 Source checks claims about thymosin beta-4 and its short piece. We identify whether the work involved patients, animals, or cells grown in a lab. Then we tell you what changed and what did not.

The word 'source' means the study where a claim began. It does not mean a supplier. Nothing here is sold, shipped, or prepared for use.

We don't fill a prescription, book a visit, or direct your care. The aim is narrower. Before you speak with your doctor, you have a clear report of what the studies found.

Why "source" means a study, not a seller

On this site, a 'source' is the study or agency page behind a claim. The site offers no compound. There is no stock, seller, or path to a purchase here.

We compare the claim with the paper that people cite for it. Sometimes they match. Sometimes an animal result has been retold as if it happened in people.

When no sound paper supports a claim, we say so. That purpose explains the name. No reader should mistake it for a storefront.

How we keep a study from saying more than it found

When a claim uses a number, the study must support that number. You can check every reference. Tests that found no help count too, because a fair review can't hide them.

A seller may blur the short chain with full thymosin beta-4. We don't. When researchers used the whole protein, we say that plainly.

If the research stops, our answer stops too. Links take you to government pages, medical journals, and ClinicalTrials.gov, never sellers. Your next step stays in your hands.